# US 2014/0154225 A1 · Method for combined conditioning and chemoselection in a single cycle

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154225 A1
- Document ID: US20140154225A1
- Status: Published application
- Kind: A1
- Application number: 14/112,878
- Filed: 2012-04-20
- Published: 2014-06-05
- Earliest claimed: 2011-04-20
- Assignees: The Regents of the University of California
- Inventors: Noriyuki Kasahara; Robert H. Schiestl; Katrin Hacke; Akos Szakmary; Gay M. Crooks
- Web page: https://patentgrep.com/patent/US20140154225A1

## CPC

- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- A61K 31/52: Purines, e.g. adenine
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of radiation-free hematopoietic stem cell (HSC) transplantation comprises administering to a mammalian subject one or two doses of 2 to 10 mg/kg body weight of a purine base analog, such as 6TG as a pre-conditioning step. The method further comprises engrafting into the subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs within 48 to 72 hours of the pre-conditioning step; and administering to the subject about 1 to 5 mg/kg of the purine base analog every two to four days for two to eight weeks following the engrafting step. The method is performed in the absence of pre-conditioning via radiation. The subject is therefore not treated with myeloablative radiation in preparation for transplantation, and thus the subject is free of myeloablative radiation-induced toxicity.

## Claims

### Claim 1

A method of radiation-free hematopoietic stem cell (HSC) transplantation, the method comprising:
(a) administering to a mammalian subject one or two doses of 2 to 10 mg/kg body weight of a purine base analog selected from 6-thioguanine (6TG), 6-mercaptopurine (6-MP), or azathiopurine (AZA), as a pre-conditioning step;
(b) engrafting into the subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs within 48 to 72 hours of the pre-conditioning step; and
(c) administering to the subject about 1 to 5 mg/kg of the purine base analog every two to four days for two to eight weeks following the engrafting step;
wherein the method is performed in the absence of pre-conditioning via radiation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the purine base analog is 6TG.

### Claim 3 (depends on 1)

The method of claim 1, wherein the total 6TG dosage administered to the subject does not exceed 105 mg.

### Claim 4 (depends on 1)

The method of claim 1, wherein the total 6TG dosage administered to the subject does not exceed 75 mg.

### Claim 5 (depends on 1)

The method of claim 1, wherein the administering of step (c) is performed every 3 days and for not more than four weeks following the engrafting step.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject exhibits over 75% genetically modified hematopoietic cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject exhibits over 95% genetically modified hematopoietic cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein the HPRT-deficient HSCs to be transplanted have been rendered HPRT-deficient via introduction of sequences encoding zinc finger nucleases (ZFNs), transcriptional activator-like effector nucleases (TALENs), small fragment homologous recombination (SFHR) template strands, inhibitory RNAs (siRNAs) or microRNAs (miRNAs), antisense RNAs, trans-splicing RNAs, ribozymes, intracellular antibodies, or dominant-negative or competitive inhibitor proteins.

### Claim 9 (depends on 1)

The method of claim 1, wherein the HPRT-deficient HSCs to be transplanted have been genetically modified.

### Claim 10 (depends on 1)

The method of claim 1, wherein the transplanted HSCs are autologous or syngeneic.

### Claim 11 (depends on 1)

The method of claim 1, wherein the transplanted HSCs are allogeneic.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is not treated with myeloablative radiation.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject has a hereditary or genetic disorder, an acquired disease affecting lymphohematopoietic cells, or a lymphohematopoietic malignancy.
